In medical terminology, CIN stands for cervical intraepithelial neoplasia, a condition where abnormal cells develop on the surface of the cervix. CIN is not cancer, but it is considered a precancerous change that, if left untreated at higher grades, can eventually develop into cervical cancer. It is graded on a scale from 1 to 3 based on how much of the cervical lining is affected by abnormal cells.
How CIN Is Graded
The CIN grading system reflects how deeply abnormal cells extend into the thin layer of tissue covering the cervix. CIN 1 means only the lower third of that lining contains abnormal cells. CIN 2 and CIN 3 involve progressively more of the tissue, with CIN 3 meaning abnormal cells span nearly the full thickness. The critical dividing line between precancer and actual cancer is whether those abnormal cells break through the base of the lining and invade deeper tissue. As long as they stay within the surface layer, the condition remains precancerous.
You may also see the terms LSIL and HSIL on a pathology report. These come from the Bethesda System, a newer way of classifying cervical abnormalities. LSIL (low-grade squamous intraepithelial lesion) corresponds roughly to CIN 1 and typically reflects a transient HPV infection. HSIL (high-grade squamous intraepithelial lesion) covers both CIN 2 and CIN 3 and represents true precancerous changes with greater potential to progress.
What Causes CIN
Persistent infection with high-risk strains of human papillomavirus (HPV) causes virtually all cases of CIN. HPV is extremely common, and most infections clear on their own within a year or two. The problem arises when a high-risk strain lingers for years, gradually altering cervical cells. Two strains, HPV 16 and HPV 18, are responsible for about 70% of cervical cancers worldwide. The HPV vaccine protects against seven cancer-causing strains and is the most effective way to prevent CIN from developing in the first place.
How CIN Is Diagnosed
CIN is typically discovered after an abnormal Pap smear or a positive HPV test. Neither of those tests can assign a CIN grade on their own, so the next step is a procedure called colposcopy. During colposcopy, a clinician examines the cervix under magnification after applying a dilute vinegar solution. Abnormal cells dehydrate and turn white when exposed to this solution, making them visible. An iodine solution may also be applied; healthy tissue absorbs it and turns brown, while abnormal areas stay pale or yellowish.
Once suspicious areas are identified, small tissue samples (biopsies) are taken from those spots and sent to a lab. It is the biopsy, not the Pap smear, that confirms the CIN grade. The entire process is done in a clinic visit and does not require general anesthesia, though you may feel pressure or mild cramping during the biopsies.
Does CIN Always Progress to Cancer?
No, and this is one of the most important things to understand about a CIN diagnosis. Many cases, especially CIN 1 and CIN 2, resolve on their own without treatment. In a study of women under 25 with CIN 2 who were monitored rather than treated immediately, 76% saw their abnormal cells disappear completely, and another 12% improved to CIN 1. Only 12% stayed the same, and none developed invasive cancer during the follow-up period.
CIN 3 is a different story. In the same research, 71% of CIN 3 cases persisted without improving or worsening, and only about 29% showed any regression. While none of those patients progressed to invasive cancer either, the higher persistence rate is why CIN 3 is treated more aggressively. The overall takeaway: a CIN diagnosis is not a cancer diagnosis, and your doctor will factor in the grade, your age, and your HPV status when deciding whether to monitor or treat.
How CIN Is Treated
CIN 1 is generally monitored rather than treated, since it reflects a low-grade change that often clears as the immune system deals with the underlying HPV infection. Follow-up testing at regular intervals confirms whether the abnormality is resolving or progressing.
CIN 2 and CIN 3 are more likely to require treatment. The preferred approach in most settings is an excisional procedure called LEEP (loop electrosurgical excision procedure), which uses a thin heated wire loop to remove the abnormal tissue. The removed tissue is sent to a lab, which serves a dual purpose: it treats the lesion and provides a sample to confirm there is nothing more serious underneath. This is a key advantage over ablation methods like cryotherapy (freezing) or thermal ablation (heat), which destroy abnormal tissue but leave nothing behind to examine. Current guidelines from the American Society for Colposcopy and Cervical Pathology state that excision is preferred over ablation for CIN 2 and CIN 3, though ablation remains an acceptable option in certain situations or in settings where excision is not available.
Recovery After Treatment
LEEP is an outpatient procedure, and full recovery takes about four weeks. Mild cramping for a few days afterward is common. You should avoid strenuous exercise for at least one week and hold off on sexual intercourse for at least four weeks while the cervix heals. Some spotting or light bleeding is normal during recovery. If you notice bleeding when you resume exercise, stop and give your body more time.
Follow-Up After Treatment
Treatment for CIN 2 or CIN 3 is highly effective, but follow-up is essential because there is a small risk of recurrence. Current guidelines recommend HPV testing or a combination of HPV and Pap testing every three years after treatment. If only Pap testing is available, it should be done annually. This surveillance schedule continues for at least 25 years and can extend beyond that as long as you are in good health. The long follow-up window reflects the fact that HPV-related changes can sometimes reappear years later.
Impact on Future Pregnancies
If you are planning to have children, it is worth knowing that cervical treatment has a small but measurable effect on pregnancy outcomes. A large Cochrane review found that fertility itself is not reduced after CIN treatment. First-trimester miscarriage rates were similar between treated and untreated women (about 9.8% versus 8.4%). However, second-trimester miscarriage (between 12 and 24 weeks) was higher in women who had undergone treatment: 1.6% compared to 0.4% in untreated women. The increased risk of preterm birth after cervical procedures is well documented and is thought to result from removal of cervical tissue that helps keep the cervix closed during pregnancy. If you have had a LEEP or similar procedure, your obstetric provider can monitor cervical length during pregnancy to catch any issues early.